NIH Funding Opportunities (Notices, PA, RFA)

Subscribe to NIH Funding Opportunities (Notices, PA, RFA) feed
Weekly Funding Opportunities and Policy Notices from the National Institutes of Health.
Updated: 1 hour 59 sec ago

Additional Awards Eligible for PA-21-071 Research Supplements to Promote Diversity in Health-Related Research (Admin Supp)

Mon, 2022-08-29 05:01
Notice NOT-OD-22-206 from the NIH Guide for Grants and Contracts

Pre-Solicitation Notice: Mycobacterium Tuberculosis (MTB) Quality Assessment Program (TBQA), RFP: 75N93022R00015

Fri, 2022-08-26 12:12
Notice NOT-AI-22-073 from the NIH Guide for Grants and Contracts

CCRP Initiative: NIH Countermeasures Against Chemical Threats (CounterACT) Basic Research on Chemical Threats that Affect the Nervous System (R01 Clinical Trial Not Allowed)

Fri, 2022-08-26 03:27
Funding Opportunity PAR-23-027 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications for basic research projects on chemical warfare agents, toxic industrial chemicals, and pesticides that have primary or secondary effects on the nervous system. Chemical threats are toxic compounds that could be used in a terrorist attack or accidentally released from industrial production, storage, or shipping. Projects supported by this FOA are expected to generate data that elucidate mechanisms of toxicity of these agents, possible new manifestations of toxic exposures, and potential new targets for therapeutic development.

Notice of Intent to Publish a Funding Opportunity Announcement for Pediatric Heart Network Clinical Research Centers (UM1)

Thu, 2022-08-25 13:51
Notice NOT-HL-22-045 from the NIH Guide for Grants and Contracts

Blood Brain Barrier Response to Antibodies Targeting Beta-Amyloid (R01 - Clinical Trial Not Allowed)

Thu, 2022-08-25 13:18
Funding Opportunity PAR-22-235 from the NIH Guide for Grants and Contracts. This initiative is designed to promote discovery of cellular and molecular mechanisms that underlie brain blood vessels responses to passive anti-beta-amyloid immunotherapy that result in amyloid-related imaging abnormalities (ARIA). The goal is to establish an understanding of molecular mechanisms that can be targeted to protect the blood brain barrier (BBB), and thus the brain blood vessels, during therapeutic interventions that target beta-amyloid.

The Metastasis Research Network (MetNet): MetNet Research Projects (U01 Clinical Trial Not Allowed)

Thu, 2022-08-25 02:00
Funding Opportunity PAR-22-234 from the NIH Guide for Grants and Contracts. The MetNet is a collection of Research Centers that support using systems level approaches to understand the non-linear, dynamic and emergent processes in metastasis. Considering chronological progression and biological scales, the MetNet seeks to collectively derive a more comprehensive and cohesive picture of metastasis as a whole body, systems-level problem.

NIA Research and Entrepreneurial Development Immersion (REDI): Mentored Entrepreneurial Career Development Award (K01 Clinical Trial Not Allowed)

Wed, 2022-08-24 10:39
Funding Opportunity PAR-22-227 from the NIH Guide for Grants and Contracts. The purpose of the NIA Research and Entrepreneurial Development Immersion (REDI): Mentored Entrepreneurial Career Development Award is to provide support and protected time (three to five years) for an intensive, supervised career development experience in the biomedical, behavioral, or clinical sciences leading to research independence.

NIA Research and Entrepreneurial Development Immersion (REDI): Entrepreneurship Enhancement Award (R25 Independent Clinical Trial Not Allowed)

Wed, 2022-08-24 10:33
Funding Opportunity PAR-22-226 from the NIH Guide for Grants and Contracts. The purpose of the Research and Entrepreneurial Development Immersion (REDI): NIA Entrepreneurship Enhancement Award (R25) is to promote the development of entrepreneurial training programs that are designed to broaden the skillset of graduate students and postdocs, as well as early career master's, Ph.D., and Dr.P.H. scientists, in fields relevant to the mission of NIA, including aging and Alzheimer's disease (AD) research. The goal of this program is to prepare trainees for a wide range of career paths, including those that are outside the normal research environment.

Catalyst Award for Early-Stage Investigators (ESIs) Pursuing Research on HIV Comorbidities, Coinfections, and Complications (DP1- Clinical Trial Optional)

Wed, 2022-08-24 10:18
Funding Opportunity PAR-23-024 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) supports research from creative early stage investigators who propose highly innovative, pioneering studies with potential to open new areas of HIV/AIDS related to coinfections, comorbidities, and complications. Projects should reflect new and novel scientific directions that are distinct from concepts and approaches being pursued in the investigators research program or elsewhere. Projects must be consistent the scientific priorities outlined by the NIH Office of AIDS Research (OAR). These priorities have been most recently been described in NOT-OD-20-018.

NICHD Research Education Programs (R25 Clinical Trial Not Allowed)

Wed, 2022-08-24 10:04
Funding Opportunity PAR-22-224 from the NIH Guide for Grants and Contracts. This FOA will support creative educational activities that focus primarily on research skills development. . Although activities focused primarily on mentoring activities or professional skills development are not within the scope of this funding announcement, the informal mentoring activities and professional skills development that are usually associated with courses for research skills development are permitted.

Pages